Literature DB >> 9210405

Construction, expression and characterization of chimaeric toxins containing the ribonucleolytic toxin restrictocin: intracellular mechanism of action.

D Rathore1, J K Batra.   

Abstract

Restrictocin is a ribonucleolytic toxin produced by the fungus Aspergillus restrictus. Two chimaeric toxins containing restrictocin directed at the human transferrin receptor have been constructed. Anti-TFR(scFv)-restrictocin is encoded by a gene produced by fusing the DNA encoding a single-chain antigen-combining region (scFv) of a monoclonal antibody, directed at the human transferrin receptor, at the 5' end of that encoding restrictocin. The other chimaeric toxin, restrictocin-anti-TFR(scFv), is encoded by a gene fusion containing the DNA encoding the single-chain antigen-combining region of antibody to human transferrin receptor at the 3' end of the DNA encoding restrictocin. These gene fusions were expressed in Escherichia coli, and fusion proteins purified from the inclusion bodies by simple chromatography techniques to near-homogeneity. The two chimaeric toxins were found to be equally active in inhibiting protein synthesis in a cell-free in vitro translation assay system. The chimaeric toxins were selectively toxic to the target cells in culture with potent cytotoxic activities. However, restrictocin-anti-TFR(scFv) was more active than anti-TFR(scFv)-restrictocin on all cell lines studied. By using protease and metabolic inhibitors, it can be shown that, to manifest their cytotoxic activity, the restrictocin-containing chimaeric toxins need to be proteolytically processed intracellularly and the free toxin or a fragment thereof thus generated is translocated to the target via a route involving the Golgi apparatus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9210405      PMCID: PMC1218497          DOI: 10.1042/bj3240815

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  49 in total

1.  Structures and activities of protease inhibitors of microbial origin.

Authors:  H Umezawa
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

2.  Expression of ribonucleolytic toxin restrictocin in Escherichia coli: purification and characterization.

Authors:  D Rathore; S K Nayak; J K Batra
Journal:  FEBS Lett       Date:  1996-09-02       Impact factor: 4.124

3.  The Aspergillus toxin restriction is a suitable cytotoxic agent for generation of immunoconjugates with monoclonal antibodies directed against human carcinoma cells.

Authors:  F P Conde; R Orlandi; S Canevari; D Mezzanzanica; M Ripamonti; S M Muñoz; P Jorge; M I Colnaghi
Journal:  Eur J Biochem       Date:  1989-01-02

4.  The ribosomes of Aspergillus giganteus are sensitive to the cytotoxic action of alpha-sarcin.

Authors:  S P Miller; J W Bodley
Journal:  FEBS Lett       Date:  1988-03-14       Impact factor: 4.124

5.  The sequence of the nucleotides at the alpha-sarcin cleavage site in rat 28 S ribosomal ribonucleic acid.

Authors:  Y L Chan; Y Endo; I G Wool
Journal:  J Biol Chem       Date:  1983-11-10       Impact factor: 5.157

6.  Complete amino acid sequence of the Aspergillus cytotoxin mitogillin.

Authors:  J L Fernandez-Luna; C López-Otin; F Soriano; E Méndez
Journal:  Biochemistry       Date:  1985-02-12       Impact factor: 3.162

7.  The primary structure of the cytotoxin restrictocin.

Authors:  C López-Otín; D Barber; J L Fernández-Luna; F Soriano; E Méndez
Journal:  Eur J Biochem       Date:  1984-09-17

8.  The site of action of alpha-sarcin on eukaryotic ribosomes. The sequence at the alpha-sarcin cleavage site in 28 S ribosomal ribonucleic acid.

Authors:  Y Endo; I G Wool
Journal:  J Biol Chem       Date:  1982-08-10       Impact factor: 5.157

9.  The primary structure of the cytotoxin alpha-sarcin.

Authors:  G Sacco; K Drickamer; I G Wool
Journal:  J Biol Chem       Date:  1983-05-10       Impact factor: 5.157

10.  Immunoconjugate generation between the ribosome inactivating protein restrictocin and an anti-human breast carcinoma MAB.

Authors:  R Orlandi; S Canevari; F P Conde; F Leoni; D Mezzanzanica; M Ripamonti; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more
  6 in total

1.  Production and characterization of a single-chain Fv antibody-alkaline phosphatase fusion protein specific for clenbuterol.

Authors:  Xixia Liu; Hong Wang; Yan Liang; Jinyi Yang; Hongbin Zhang; Hongtao Lei; Yudong Shen; Yuanming Sun
Journal:  Mol Biotechnol       Date:  2010-05       Impact factor: 2.695

2.  Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins.

Authors:  A Goyal; J K Batra
Journal:  Biochem J       Date:  2000-01-15       Impact factor: 3.857

3.  Construction of single chain Fv antibody against transferrin receptor and its protein fusion with alkaline phosphatase.

Authors:  Dao-Feng Yang; Hui-Fen Zhu; Zhi-Hua Wang; Guan-Xin Shen; De-Ying Tian
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

Review 4.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

5.  Potential antitumor therapeutic application of Grimontia hollisae thermostable direct hemolysin mutants.

Authors:  Sheng-Cih Huang; Yu-Kuo Wang; Wan-Ting Huang; Tsam-Ming Kuo; Bak-Sau Yip; Tien-Hsiung Thomas Li; Tung-Kung Wu
Journal:  Cancer Sci       Date:  2015-03-10       Impact factor: 6.716

6.  Inclusion of a Furin Cleavage Site Enhances Antitumor Efficacy against Colorectal Cancer Cells of Ribotoxin α-Sarcin- or RNase T1-Based Immunotoxins.

Authors:  Javier Ruiz-de-la-Herrán; Jaime Tomé-Amat; Rodrigo Lázaro-Gorines; José G Gavilanes; Javier Lacadena
Journal:  Toxins (Basel)       Date:  2019-10-12       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.